IPP Bureau

Novartis unveils results of survey on chronic myeloid leukemia
Novartis unveils results of survey on chronic myeloid leukemia

By IPP Bureau - June 12, 2023

Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

By IPP Bureau - June 12, 2023

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease

Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection
Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection

By IPP Bureau - June 12, 2023

Mandaviya inaugurates CGHS Wellness Centres in Chandigarh and Panchkula
Mandaviya inaugurates CGHS Wellness Centres in Chandigarh and Panchkula

By IPP Bureau - June 12, 2023

Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023

Asence Pharma commences new plant at Ranoli, Vadodara
Asence Pharma commences new plant at Ranoli, Vadodara

By IPP Bureau - June 10, 2023

The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement

Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany
Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany

By IPP Bureau - June 10, 2023

The EU certification will support supplies of drug products registered in Europe, from this manufacturing site

Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities
Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities

By IPP Bureau - June 10, 2023

The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52

Univar Solutions expands specialty pharmaceutical and nutraceutical ingredient portfolios with Grace Syloid FP Silica
Univar Solutions expands specialty pharmaceutical and nutraceutical ingredient portfolios with Grace Syloid FP Silica

By IPP Bureau - June 09, 2023

Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network

Cosette Pharmaceuticals acquires Intrarosa from Endoceutics
Cosette Pharmaceuticals acquires Intrarosa from Endoceutics

By IPP Bureau - June 09, 2023

Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product

Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University
Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University

By IPP Bureau - June 09, 2023

Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration

Health Ministry organizes webinar on Non-Alcoholic Fatty Liver Diseases
Health Ministry organizes webinar on Non-Alcoholic Fatty Liver Diseases

By IPP Bureau - June 09, 2023

Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level

Zydus receives final approval from USFDA for Esomeprazole Magnesium
Zydus receives final approval from USFDA for Esomeprazole Magnesium

By IPP Bureau - June 09, 2023

Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)

Ecolab expands biologics resin manufacturing facility in Pennsylvania
Ecolab expands biologics resin manufacturing facility in Pennsylvania

By IPP Bureau - June 09, 2023

New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.

Lonza signs VPPA for solar power supply with Ignis
Lonza signs VPPA for solar power supply with Ignis

By IPP Bureau - June 09, 2023

Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.

Croda breaks ground on lipid manufacturing facility in Pennsylvania
Croda breaks ground on lipid manufacturing facility in Pennsylvania

By IPP Bureau - June 09, 2023

Construction will begin this year with the new capacity anticipated by 2025

Latest Stories

Interviews

Packaging